Susquehanna International Group
KPTI icon

Susquehanna International Group’s Karyopharm Therapeutics KPTI Stock Holding History

Susquehanna International Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.82M Buy
865,000
+544,100
+170% +$4.15M ﹤0.01% 4303
2025
Q4 		$2.36M Buy
320,900
+202,000
+170% +$1.24M ﹤0.01% 5298
2025
Q3 		$778K Buy
118,900
+102,300
+616% +$550K ﹤0.01% 7934
2025
Q2 		$71.5K Sell
16,600
-47,200
-74% -$232K ﹤0.01% 11976
2025
Q1 		$239K Buy
63,800
+56,453
+768% +$482K ﹤0.01% 10571
2024
Q4 		$74.9K Sell
7,347
-4,873
-40% -$58.9K ﹤0.01% 11504
2024
Q3 		$152K Sell
12,220
-4,100
-25% -$51K ﹤0.01% 10727
2024
Q2 		$213K Buy
16,320
+10,767
+194% +$178K ﹤0.01% 10224
2024
Q1 		$126K Buy
5,553
+1,766
+47% +$31K ﹤0.01% 11060
2023
Q4 		$49.4K Buy
3,787
+27
+0.7% +$364 ﹤0.01% 11717
2023
Q3 		$75.6K Buy
3,760
+460
+14% +$10.3K ﹤0.01% 11099
2023
Q2 		$88.6K Sell
3,300
-1,893
-36% -$81.5K ﹤0.01% 11038
2023
Q1 		$303K Sell
5,193
-667
-11% -$32.9K ﹤0.01% 9695
2022
Q4 		$299K Sell
5,860
-4,007
-41% -$278K ﹤0.01% 9109
2022
Q3 		$808K Sell
9,867
-7,626
-44% -$570K ﹤0.01% 7187
2022
Q2 		$1.18M Sell
17,493
-22,154
-56% -$2.03M ﹤0.01% 6119
2022
Q1 		$4.38M Buy
39,647
+35,500
+856% +$4.42M ﹤0.01% 3860
2021
Q4 		$400K Buy
4,147
+14
+0.3% +$1.4K ﹤0.01% 9778
2021
Q3 		$361K Sell
4,133
-5,594
-58% -$581K ﹤0.01% 10166
2021
Q2 		$1.51M Buy
9,727
+5,360
+123% +$778K ﹤0.01% 6630
2021
Q1 		$689K Sell
4,367
-4,893
-53% -$1.03M ﹤0.01% 8704
2020
Q4 		$2.15M Buy
9,260
+813
+10% +$188K ﹤0.01% 4939
2020
Q3 		$1.85M Buy
8,447
+4,720
+127% +$1.15M ﹤0.01% 4766
2020
Q2 		$1.06M Sell
3,727
-12,886
-78% -$3.81M ﹤0.01% 5794
2020
Q1 		$4.79M Sell
16,613
-5,400
-25% -$1.49M ﹤0.01% 2622
2019
Q4 		$6.33M Buy
22,013
+5,080
+30% +$1.1M ﹤0.01% 2648
2019
Q3 		$2.44M Buy
16,933
+8,953
+112% +$1.21M ﹤0.01% 3827
2019
Q2 		$717K Sell
7,980
-433
-5% -$34.8K ﹤0.01% 6450
2019
Q1 		$737K Buy
8,413
+7,626
+969% +$845K ﹤0.01% 5584
2018
Q4 		$111K Sell
787
-853
-52% -$144K ﹤0.01% 8168
2018
Q3 		$419K Sell
1,640
-87
-5% -$24K ﹤0.01% 6855
2018
Q2 		$440K Sell
1,727
-6,320
-79% -$1.56M ﹤0.01% 7050
2018
Q1 		$1.62M Buy
8,047
+2,694
+50% +$537K ﹤0.01% 4313
2017
Q4 		$771K Buy
5,353
+2,926
+121% +$470K ﹤0.01% 5754
2017
Q3 		$400K Sell
2,427
-480
-17% -$68.8K ﹤0.01% 6916
2017
Q2 		$395K Sell
2,907
-233
-7% -$34.5K ﹤0.01% 7076
2017
Q1 		$605K Sell
3,140
-2,720
-46% -$437K ﹤0.01% 6142
2016
Q4 		$826K Buy
5,860
+4,253
+265% +$575K ﹤0.01% 5931
2016
Q3 		$234K Sell
1,607
-53
-3% -$6.37K ﹤0.01% 7326
2016
Q2 		$167K Sell
1,660
-1,853
-53% -$241K ﹤0.01% 7749
2016
Q1 		$470K Buy
3,513
+2,613
+290% +$288K ﹤0.01% 6514
2015
Q4 		$179K Sell
900
-4,813
-84% -$1.04M ﹤0.01% 8513
2015
Q3 		$902K Buy
5,713
+3,286
+135% +$879K ﹤0.01% 5970
2015
Q2 		$990K Buy
2,427
+67
+3% +$29K ﹤0.01% 6242
2015
Q1 		$1.08M Buy
2,360
+413
+21% +$178K ﹤0.01% 5602
2014
Q4 		$1.09M Sell
1,947
-1,353
-41% -$769K ﹤0.01% 5691
2014
Q3 		$1.73M Buy
+3,300
New +$1.86M ﹤0.01% 4862

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Susquehanna International Group's KPTI Position: Q1 2026 in Review

Susquehanna International Group reduced its Karyopharm Therapeutics (KPTI) stake by 84% in Q1 2026, selling an estimated $942K and leaving 24,138 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #12120.

Susquehanna International Group first reported a position in KPTI in Q4 2014 and has held it in 41 quarters since. The position peaked at $10.5M in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Susquehanna International Group held 24,138 shares of Karyopharm Therapeutics worth $134K as of Q1 2026.
  • Susquehanna International Group sold 123,560 Karyopharm Therapeutics shares in Q1 2026, an estimated $942K.
  • Karyopharm Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12120 holding.
  • Susquehanna International Group first reported a position in Karyopharm Therapeutics in Q4 2014 and has held it in 41 quarters since.
  • Susquehanna International Group's Karyopharm Therapeutics position peaked at $10.5M in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.